Introduction

The trigeminal sensory nerves comprise primary neuronal cell body situated in the trigeminal ganglion (TG), peripheral axons innervate the corresponding regions of the craniofacial structures and the central terminals make synapse with second order neurons in the trigeminal sensory nuclei (TSN), located in the brainstem. The TSN is subdivided into the principal or main sensory nucleus, subnuclei oralis (Vo), subnuclei interpolaris (Vi) and subnuclei caudalis (SpVc). Among these second order neurons, the SpVc receives nociceptive afferent inputs activated by innocuous thermal stimuli or noxious stimuli. There are several common acute and chronic painful ailments affecting the craniofacial region, such as, temporomandibular disorders, toothaches, headaches, and trigeminal neuralgia. The exact mechanism of pain control in the trigeminal system is still under investigation as per the trigeminal system appears to be greatly different from the spinal system.

Abstract

Management of chronic pain is one of the most important reason to which medications are given. Traditional medicines which have been used to relieve pain are having a number of limitations. Therefore, novel therapies for pain treatment are essential. Our nervous system can process any kind of injurious stimuli, which is known as nociception. The mechanism of nociception involves a complex interaction of peripheral and central nervous system structures. Brain or cerebral cortex has its own controlling mechanism for pain perception. Trigeminal nerve is the fifth cranial nerve and it receives pain sensation from oro- and craniofacial region and sends the information up to cortex. Recent investigations demonstrate another important role of cortical neurons in addition to pain perception, that is, corticotrigeminal (cortex to trigeminal) pathway excites neurons in the trigeminal nerve that leads to decrease in the pain response induced by noxious stimuli. Thus, as this mechanism can be induced at early stage of nociception, it may reduce the pain sensation. So, the corticotrigeminal pathway could be a new potential target for pain therapies. This short review revisits the concepts how stimulation of primary somatosensory cortex can be transmitted via corticotrigeminal tract which aim for the inhibitory neurons in spinal trigeminal nucleus caudalis (SpVc) and thus potentially generate a feedforward inhibition, explaining the pain modulatory role of the corticotrigeminal pathway.

Key words: Corticotrigeminal pathway, feedforward inhibition, trigeminal spinal caudalis,
The SpVc (subnucleus caudalis) owns an intrinsic circuitry for nociceptive processing allowing substantial interaction between the afferent inputs from peripheral tissues and from descending projections from several areas of central nervous system (CNS), including the reticular formation, raphe nuclei, parabrachial area, locus coeruleus, hypothalamus, amygdala, and several areas of the cerebral cortex (e.g. sensorimotor; anterior cingulate; prefrontal).2

CNS has an intrinsic well characterized nociceptive modulatory mechanism known as descending pain modulatory circuit (the periaqueductal gray-rostroventral medulla system).4,5 This mechanism suppresses pain (most commonly by releasing endogenous opioids, e.g. encephalin, endorphins) at initial stages of nociceptive processing in the second order neurons which receive nociceptive afferents as this could ultimately minimize the transmission of pain signals to higher brain areas.3

Pain can be described in terms of three hierarchical stages such as, sensory-discriminative, motivational-affective and cognitive-evaluative elements (e.g. thoughts concerning the cause of pain).6 The forebrain structures, comprising the amygdala and neocortex has been known to regulate the cognitive aspect of pain, offers an indirect influence over the descending pain modulatory system.7 In addition to this indirect influence, it has been observed in some animal models that, dense anatomical projection fibers from the somatosensory cortex directly target second order neurons in the trigeminal nuclei and can alter the sensory processing.8,9 One of the first reports of direct projections from cortical areas towards trigeminal sensory nuclei (TSN), in cat was suggested by Brodal et al.10 Successive research in cats showed direct inputs from primary somatosensory cortex (SI)11 and the secondary somatosensory cortex (SII)12 to the subnucleus caudalis (SpVc), that receive primary nociceptive afferents from the head and neck.8 In addition, direct inputs to SpVc were also observed in rats and mouse originating from SI, SII, and from the insula.9,13,14

Till to date, several studies has reported on how the corticotrigeminal pathway can affect the nociceptive processing in the SpVc. Wang et al.9 reported that after suppressing the

Figure 01: Schema of major somatosensory pathway from the craniofacial region. The cell bodies of primary afferents in the trigeminal nerve are in the trigeminal (V) ganglion and project to second-order neurons in the trigeminal brainstem sensory nuclear complex, which is made up of the trigeminal main sensory nucleus and the trigeminal spinal tract nucleus; consists three subnuclei: Oralis (Vo), interpolaris (Vi), and caudalis (Vc). These neurons may project to neurons at higher levels of the brain. (Adapted from Chichorro et al.3)
activity of the corticotrigeminal neurons in insula could decrease the expression of cFOS (a DNA binding protein, commonly used as an activity dependent cell marker along the nociceptive pathway) in SpVc, in a model of neuropathic pain.\(^9\) Likewise, it has been observed that, stimulation of either primary or secondary somatosensory cortex (SI and SII respectively) can inhibit capsaicin induced firing in SpVc.\(^{15}\) Recently, Castro et al.\(^{16}\) have tried their best to address the role of corticotrigeminal circuitry in the modulation of nociception at the level of SpVc and proposed it to be a potential therapeutic target for pain relief.\(^{16}\) This group of researchers has shown that, after cortical stimulation, efferents from SI project directly to the target interneurons in the SpVc to suppress responses to noxious stimuli and produce behavioral hypoalgesia by feedforward inhibition of projection neurons (exciting the local inhibitory neurons which then inhibit the excitatory projection neurons) through GABA\(_A\) receptor-mediated signaling.\(^{17}\)

In the aim of developing effective therapeutic approaches against craniofacial pain disorders precise understanding of the trigeminal mechanisms of pain and nociception is indispensable. This review summarizes recent advances in the study of nociceptive processing role of corticotrigeminal pathway in the SpVc, which might contribute to improvements in the existing therapeutic strategies, as well as to the development of novel analgesic therapeutics.

**Figure 02:** A. The descending pain modulatory system. The widespread source of top-down modulation arises from the cortex to the spinal trigeminal sensory nucleus (Sp5), nucleus caudalis (Sp5C); S1 – primary somatosensory cortex; S2 – secondary somatosensory cortex. (Adapted from Villanueva & Noseda\(^{18}\)). B. mCherry expressing corticotrigeminal axon terminals, following injection of the ChR2-mCherry construct in SI, and GABAergic neurons expressing GAD-GFP in SpVc. “Nerve layer” comprises central and peripheral trigeminal nerve axons. (Adapted from Castro et al.\(^{16}\))
Materials and methods

Primary scientific literatures on modulation of nociceptive perception in the TSN b the corticotrigeminal projections was accessed as per journal articles keen to clinical studies and experimental models on craniofacial pain. Online databases were searched using a set of definite search terms and keywords including the ones mentioned in the current text. Databases searched included PubMed®, Google scholar®, and MEDLINE® resources. Special attention was given to screen and to analyse information on the current concepts incorporating the nociceptive neuronal responses in SpVc and mechanisms of inhibition of noxious stimuli by cortical stimulation in the SpVc to produce analgesia, as well as future research areas delineated in this field.

Discussion

The spinal trigeminal nucleus caudalis (SpVc) receives projection fibers from the neocortex but the nociceptive processing role of this corticotrigeminal pathway in the SpVc has been under thoroughgoing investigations. So far, various well-designed experiments using anatomical, optogenetic or electrophysiological techniques have been applied in several studies to demonstrate that, descending projections from the primary somatosensory cortex (SI) may modulate the nociception as such stimulation of SI can attenuate SpVc responses induced by noxious stimuli and reverse the pain hypersensitivity.

Expressions of dense terminal plexus around GABAergic neurons formed by the corticotrigeminal axons in SpVc and In vitro stimulation of these axons excite the interneurons, and create feedforward inhibition of the projections neurons in SpVc.

In several animal models, anatomical tract tracing discovered that corticotrigeminal axonal pathways terminate densely in SpVc, such as, in rats as well as in cats. In one recent report, Castro and his colleagues used transgenic GAD-GFP mice and begun their experiments with the anticipation of existence of anatomical substrate for cortical inputs (SI) in the SpVc. They injected Cholera toxin subunit B (CTB) into the barrel cortex and showed densely distributed CTB labeled corticotrigeminal axons and varicosities, bordering the soma and dendrites of GFP expressing GABAergic neurons particularly in superficial (I-II) and deep (V-VI) laminae. This observation suggests that corticotrigeminal axons send dense and powerful inputs to SpVc, including to the inhibitory interneurons of this nucleus.

Furthermore, corticotrigeminal inputs also proposed to send anatomical substrate for feedforward inhibition of SpVc projection neurons. To determine the presence of synapse between SpVc neurons and corticotrigeminal axon terminals, a group of researchers performed in vitro recordings from groups of neurons in the superficial layers (lamina I-II), such as, GFP expressing inhibitory GABAergic neurons; projection neurons (identified by retrogradely transported fluorescent latex beads following injections in parabrachial nucleus) and unidentified neurons (labeled with neither beads nor GFP). As expected, the optogenetic stimulation of corticotrigeminal axons produced strong excitation in inhibitory neurons and as because there was small variation in latency, indicating evocation of monosynaptic responses. It is noteworthy that, these light evoked responses were ended by the administration of glutamate receptor antagonist CNQX and APV, which again suggest that these responses are arbitrated by glutamate released from corticotrigeminal pathway. On the other hand, there was weak excitation followed by strong inhibition in projection neurons evident by generation of markedly smaller magnitude of responses in these neurons than that of the GFP-GABAergic neurons.

Previously, Jacquin et al. has also reported similar feedforward inhibition that strongly modify the activity of projection neurons in trigeminal (V) subnucleus interpolaris (SpVi) in rats. The site for termination of nociceptive
afferents lies in the superficial layers (lamina I-II) of spinal dorsal horn where cortical terminals can directly modulate the neuronal activity.22 Besides, the substantia gelatinosa (lamina II) is presumed to play a key modulatory role in nociceptive transmission from periphery to central nervous system.23 Therefore, from above discussion it is necessarily clear that, cortical inputs from SI can directly modulate neurons and thus the nociceptive processing in the superficial layer of SpVc.

Nociceptive neuronal responses in SpVc can be suppressed by cortical stimulation
Stimulation of SI results in suppression of suprathreshold responses of SpVc evoked by noxious stimulation to the skin.16 Following in vivo single unit recordings from neurons in laminae V or VI in SpVc in anesthetized male rats, both before and during electrical stimulation (50 Hz) of SI, it was observed that, combined skin stimulation (current injection through subcutaneous wires in buccal region) and electrical stimulation of SI (through implanted electrode) have reduced the magnitude of responses in SpVc neurons.16 Wang et al.9 and Braz et al.24 suggested that nociceptive processing of projection neurons in the deep layer involve inputs from the interneurons of superficial layer of SpVc.9,24 Hence, it can be proposed that cortical inputs reduce nociceptive responses of superficial neurons, causing reduced activation of projection neurons that reside in both superficial and deep SpVc.

Earlier, Malmierca et al.14 also observed suppressed nociceptive responses in rat SpVc following SI stimulation (50Hz) which was found to be blocked by GABAA and glycine receptor antagonists.14 These findings are compatible with another finding by Noseda et al. that, chemically evoked cortical spreading depression involving SI can suppress responses of SpVc neurons.13 Conversely, Gojo et al.25 reported that lower frequency stimulation (10 Hz) of SI had no effect on formalin-induced changes in immediate early genes expressed by SpVc neurons.25

Inhibition of response to noxious stimuli by cortical stimulation produces analgesia
To be sure, SI stimulation has been shown to inhibit the activity of dorsal horn neurons in rats26, cats27, and monkeys28, and to ameliorate pain in humans.29,30 Interestingly, Castro et al.16 for the first time, tested and scored the grooming behaviors in rats following the SI stimulation. After applying 5% capsaicin cream over the buccal area and three types of grooming responses were observed, such as, (i) rubbing the face with forepaws; (ii) rubbing the cheek and lower lip against cage floor; (iii) scratching the face with hindpaw. The SI stimulation reduces the duration of grooming response was significantly.16 This finding reveals that cortical (SI) stimulation via corticotrigeminal inputs to SpVc inhibit the neuronal response evoked by noxious stimuli and thereby reduce the pain perception as well as produce analgesia.

Conclusion
Until now motor cortex has been given priorities over somatosensory cortex as a potential suppressor of nociception.31 To be sure, there are several chronic pain conditions which have been treated by cortical stimulation through subdural electrodes or by using noninvasive transcranial magnetic stimulation.23 However, to expand these approaches, a precise knowledge about the effective site of stimulation is inevitable. There is still a huge knowledge gap in the actual nociceptive processing in the trigeminal sensor nuclei (TSN) as it is fairly different from other body parts in structural and pharmacological features. A thorough understanding of corticotrigeminal pathway as an effective modulator of pain perception can be a promising target for therapeutic interventions to alleviate chronic debilitating craniofacial pain. Nevertheless, further investigations are required to find out the precise neuronal
References


